| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1996;61:1470-1476
© 1996 The Society of Thoracic Surgeons
Lung Cancer Research Laboratory, Thoracic Oncology Program at the Dana Farber Cancer Institute and the Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
Background. Although complete surgical resection remains the primary treatment for localized stage I non-small cell lung cancer, the cancer recurrence rate is 25% to 40%. If one could identify a subset of patients using molecular factors that contribute to tumor aggressiveness, one might improve prognosis in this group with additional treatment. High expression of angiogenesis factor viii has been associated with the presence of nodal metastases in breast cancer; here we examined its relation to survival with non-small cell lung cancer.
Methods. We examined angiogenesis using immunohistochemistry on paraffin blocks of tumor from 275 consecutive patients with stage I non-small cell lung cancer, more than 68 months of follow-up, and a 64% 5-year survival. Angiogenesis was calculated from the microvessel number per ten 200x microscope fields measured at the tumor periphery, in the center, and in the area of highest concentration.
Results. Measurements in the central area were inconsistent due to prominent necrosis. However, microvessel number recorded at the periphery and at the ``hottest'' area correlated well (r2 = 0.952; p = 0.001), and a significant survival advantage was noted for low-level expression at both areas (peripheral, p = 0.046; ``hottest'', p = 0.006). Multivariate survival analysis using angiogenesis, protooncogene erbB-2, tumor suppressor gene p53, and the proliferation marker KI-67 defined angiogenesis as the most significant prognostic factor in stage I lung cancer.
Conclusions. This molecular biologic substaging system including angiogenesis for stage I non-small cell lung cancer is independent of routine histopathologic factors and revealed an additive adverse effect with expression of several biologic markers (5-year survival: no marker [n = 51] 81%, 1 marker [n = 82] 71%, 2 markers [n = 84] 54%, and 3 to 4 markers [n = 58] 49%; p = 0.0001).
Related Article
Ann. Thorac. Surg. 1996 61: 1476.
This article has been cited by other articles:
|
|
 |
|
  H. Matsuguma, R. Nakahara, S. Igarashi, Y. Ishikawa, H. Suzuki, N. Miyazawa, S. Honjo, and K. Yokoi Pathologic stage I non small cell lung cancer with high levels of preoperative serum carcinoembryonic antigen: Clinicopathologic characteristics and prognosis J. Thorac. Cardiovasc. Surg., January 1, 2008; 135(1): 44 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Szoke, K. Kayser, I. Trojan, G. Kayser, J. Furak, L. Tiszlavicz, J.-D. Baumhakel, and H.-J. Gabius The role of microvascularization and growth/adhesion-regulatory lectins in the prognosis of non-small cell lung cancer in stage II Eur. J. Cardiothorac. Surg., May 1, 2007; 31(5): 783 - 787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Szoke, K. Kayser, J.-D. Baumhakel, I. Trojan, J. Furak, L. Tiszlavicz, J. Eller, and K. Boda Prognostic significance of microvascularization in cases of operated lung cancer Eur. J. Cardiothorac. Surg., June 1, 2005; 27(6): 1106 - 1111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W Hilbe, S Dirnhofer, F Oberwasserlechner, T Schmid, E Gunsilius, G Hilbe, E Woll, and C M Kahler CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer J. Clin. Pathol., September 1, 2004; 57(9): 965 - 969. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Buck, G. Glatting, and S. N. Reske Quantification of 18F-FDG Uptake in Non-Small Cell Lung Cancer: A Feasible Prognostic Marker? J. Nucl. Med., August 1, 2004; 45(8): 1274 - 1276. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Tanaka, K. Yanagihara, Y. Otake, Y. Kawano, R. Miyahara, K. Takenaka, H. Katakura, S. Ishikawa, H. Ito, and H. Wada Prognostic Factors in Resected Pathologic (p-) Stage IIIA-N2, Non-Small-Cell Lung Cancer Ann. Surg. Oncol., June 1, 2004; 11(6): 612 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Phillips and L. M. Birnby Nitric oxide modulates caveolin-1 and matrix metalloproteinase-9 expression and distribution at the endothelial cell/tumor cell interface Am J Physiol Lung Cell Mol Physiol, May 1, 2004; 286(5): L1055 - L1065. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Pold, L. X. Zhu, S. Sharma, M. D. Burdick, Y. Lin, P. P. N. Lee, A. Pold, J. Luo, K. Krysan, M. Dohadwala, et al. Cyclooxygenase-2-Dependent Expression of Angiogenic CXC Chemokines ENA-78/CXC Ligand (CXCL) 5 and Interleukin-8/CXCL8 in Human Non-Small Cell Lung Cancer Cancer Res., March 1, 2004; 64(5): 1853 - 1860. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Reed General thoracic surgery and the Southern Thoracic Surgical Association: the second 25 years Ann. Thorac. Surg., November 1, 2003; 76(90050): S14 - 16. [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Moran, D. A. Arenberg, C.-C. Huang, T. J. Giordano, D. G. Thomas, D. E. Misek, G. Chen, M. D. Iannettoni, M. B. Orringer, S. Hanash, et al. RANTES Expression Is a Predictor of Survival in Stage I Lung Adenocarcinoma Clin. Cancer Res., December 1, 2002; 8(12): 3803 - 3812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Bepler, A. Gautam, L. M. McIntyre, A. F. Beck, D. S. Chervinsky, Y.-C. Kim, D. M. Pitterle, and A. Hyland Prognostic Significance of Molecular Genetic Aberrations on Chromosome Segment 11p15.5 in Non-Small-Cell Lung Cancer J. Clin. Oncol., March 1, 2002; 20(5): 1353 - 1360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ramnath, F. J. Hernandez, D.-F. Tan, J. A. Huberman, N. Natarajan, A. F. Beck, A. Hyland, I. T. Todorov, J. S.J. Brooks, and G. Bepler MCM2 Is an Independent Predictor of Survival in Patients With Non-Small-Cell Lung Cancer J. Clin. Oncol., November 15, 2001; 19(22): 4259 - 4266. [Abstract] [Full Text]
|
|
|
|
|
|
F. Tanaka, Y. Otake, K. Yanagihara, Y. Kawano, R. Miyahara, M. Li, T. Yamada, N. Hanaoka, K. Inui, and H. Wada Evaluation of Angiogenesis in Non-small Cell Lung Cancer: Comparison between Anti-CD34 Antibody and Anti-CD105 Antibody Clin. Cancer Res., November 1, 2001; 7(11): 3410 - 3415. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Steels, M. Paesmans, T. Berghmans, F. Branle, F. Lemaitre, C. Mascaux, A.P. Meert, F. Vallot, J.J. Lafitte, and J.P. Sculier Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis Eur. Respir. J., October 1, 2001; 18(4): 705 - 719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. D'Amico, T. A. Aloia, M.-B. H. Moore, D. H. Conlon, J. E. Herndon II, M. S. Kinch, and D. H. Harpole Jr Predicting the sites of metastases from lung cancer using molecular biologic markers Ann. Thorac. Surg., October 1, 2001; 72(4): 1144 - 1148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Aloia, D. H. Harpole Jr, C. E. Reed, C. Allegra, M.-B. H. Moore, J. E. Herndon II, and T. A. D'Amico Tumor marker expression is predictive of survival in patients with esophageal cancer Ann. Thorac. Surg., September 1, 2001; 72(3): 859 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Phillips, L. M. Birnby, A. Narendran, and W. L. Milonovich Nitric oxide modulates capillary formation at the endothelial cell-tumor cell interface Am J Physiol Lung Cell Mol Physiol, July 1, 2001; 281(1): L278 - L290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.F. Vansteenkiste and S.G. Stroobants The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology Eur. Respir. J., April 1, 2001; 17(4): 802 - 820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Koukourakis, A. Giatromanolaki, P. E. Thorpe, R. A. Brekken, E. Sivridis, S. Kakolyris, V. Georgoulias, K. C. Gatter, and A. L. Harris Vascular Endothelial Growth Factor/KDR Activated Microvessel Density versus CD31 Standard Microvessel Density in Non-Small Cell Lung Cancer Cancer Res., June 1, 2000; 60(11): 3088 - 3095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. D’Amico, T. A. Aloia, M.-B. H. Moore, J. E. Herndon II, K. R. Brooks, C. L. Lau, and D. H. Harpole Jr Molecular biologic substaging of stage I lung cancer according to gender and histology Ann. Thorac. Surg., March 1, 2000; 69(3): 882 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Vansteenkiste, S. G. Stroobants, P. J. Dupont, P. R. De Leyn, E. K. Verbeken, G. J. Deneffe, L. A. Mortelmans, and M. G. Demedts Prognostic Importance of the Standardized Uptake Value on 18F-Fluoro-2-Deoxy-Glucose–Positron Emission Tomography Scan in Non–Small-Cell Lung Cancer: An Analysis of 125 Cases J. Clin. Oncol., October 1, 1999; 17(10): 3201 - 3206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. SHIJUBO, T. UEDE, S. KON, M. MAEDA, T. SEGAWA, A. IMADA, M. HIRASAWA, and S. ABE Vascular Endothelial Growth Factor and Osteopontin in Stage I Lung Adenocarcinoma Am. J. Respir. Crit. Care Med., October 1, 1999; 160(4): 1269 - 1273. [Abstract] [Full Text]
|
|
|
|
|
|
T. A. D'Amico, MD, M. Massey, MD, J. E. Herndon II, PhD, M.-B. Moore, and D. H. Harpole Jr A BIOLOGIC RISK MODEL FOR STAGE I LUNG CANCER: IMMUNOHISTOCHEMICAL ANALYSIS OF 408 PATIENTS WITH THE USE OF TEN MOLECULAR MARKERS J. Thorac. Cardiovasc. Surg., April 1, 1999; 117(4): 736 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Harpole Jr Invited commentary Ann. Thorac. Surg., October 1, 1998; 66(4): 1163 - 1164. [Full Text] [PDF]
|
|
|
|
|
|
H. Imoto, T. Osaki, S. Taga, A. Ohgami, Y. Ichiyoshi, and K. Yasumoto Vascular endothelial growth factor expression in non-small-cell lungcancer: Prognostic significance in squamous cell carcinoma J. Thorac. Cardiovasc. Surg., May 1, 1998; 115(5): 1007 - 1011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. G. Duarte, B. L. Bufkin, M. F. Pennington, A. A. Gal, C. Cohen, A. S. Kosinski, K. A. Mansour, and J. I. Miller Angiogenesis As A Predictor Of Survival After Surgical Resection For Stage I Non-Small-Cell Lung Cancer J. Thorac. Cardiovasc. Surg., March 1, 1998; 115(3): 652 - 659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Soslow, L. Ying, and N. K. Altorki EXPRESSION OF ACIDIC FIBROBLAST GROWTH FACTOR IN BARRETT'S ESOPHAGUS AND ASSOCIATED ESOPHAGEAL ADENOCARCINOMA J. Thorac. Cardiovasc. Surg., November 1, 1997; 114(5): 838 - 843. [Abstract] [Full Text]
|
|
|
|
|
|
D. S. Winlaw Angiogenesis in the Pathobiology and Treatment of Vascular and Malignant Diseases Ann. Thorac. Surg., October 1, 1997; 64(4): 1204 - 1211. [Abstract] [Full Text]
|
|
|
|
|
|
R. J. Lewis, R. J. Caccavale, G. E. Sisler, J.-P. Bocage, and J. W. Mackenzie One Hundred Video-Assisted Thoracic Surgical Simultaneously Stapled Lobectomies Without Rib Spreading Ann. Thorac. Surg., May 1, 1997; 63(5): 1415 - 1421. [Abstract] [Full Text]
|
|
|
|
|
|
R. J. Landreneau, D. J. Sugarbaker, M. J. Mack, S. R. Hazelrigg, J. D. Luketich, L. Fetterman, M. J. Liptay, S. Bartley, T. M. Boley, R. J. Keenan, et al. WEDGE RESECTION VERSUS LOBECTOMY for STAGE I (T1 N0 M0) NON-SMALL-CELL LUNG CANCER J. Thorac. Cardiovasc. Surg., April 1, 1997; 113(4): 691 - 700. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
